Results 191 to 200 of about 920,248 (271)

The future of hepatology: Preventing liver disease together with the public, scientists and artificial intelligence. [PDF]

JHEP Rep
Laevens BPM, Meeßen C, Pijpers FP, Bruns T, Chen Y, Loomba R, Jakhar N, Arning K, Schneider KM, Schneider CV.   +9 more
europepmc   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Community case study: overcoming barriers to social participation for improved local health governance in Madagascar. [PDF]

Front Public Health
Petit D, Rajan D, Koch K, Poulussen C, Rakotomanga JDM, Rajaonarison M, Bajnóczki C, Brousse S, Kalambay H, Rambinintsoanomenjanahary SI, Rohrer-Herold K.   +10 more
europepmc   +1 more source

Training Opportunities Within the National Institute of Arthritis and Musculoskeletal and Skin Diseases

Arthritis &Rheumatology, EarlyView.
Janelle Hauserman, Isaah Vincent
wiley   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

A Good Society (and how we make it). [PDF]

J Epidemiol Community Health
Pickett KE.
europepmc   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

The European Union's Civil Society Strategy: a welcome milestone that now requires sustained operational support. [PDF]

Health Aff Sch
Rajan D.
europepmc   +1 more source

Defining a comprehensive set of value assessment criteria for funders of drug repurposing initiatives

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aims to develop a structured list of value assessment criteria for drug repurposing (DR) projects designed to support consistent, evidence‐informed decision‐making by funders. The assessment criteria were developed within the REMEDi4ALL project, a multi‐stakeholder Horizon Europe funded initiative to advance DR and were validated ...
Dalma Hosszú, Kristóf Gyöngyösi, András Perényi, Helene G. van der Meer, Dunja Huijbers, Pan Pantziarka, András Inotai, Donald C. Lo, Rick Thompson, Zoltán Kaló, Marcell Csanádi   +10 more
wiley   +1 more source